The neurofibromin GAP-related domain rescues endothelial but not neural crest development in Nf1-/- mice

Journal of Clinical Investigation

Volumn 116, Issue 9, 2006, Pages 2378-2384

  Ismat, Fraz A ^a,b   Xu, Junwang ^b   Min, Min Lu ^b   Epstein, Jonathan A ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NEUROFIBROMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM; GENETIC TRANSFECTION; LETHALITY; MOUSE; NEURAL CREST; NEUROFIBROMATOSIS; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; COS CELLS; DNA PRIMERS; ENDOTHELIUM, VASCULAR; GENOTYPE; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; NEURAL CREST; NEUROFIBROMIN 1; RAS PROTEINS; TRANSFECTION;

EID: 33748298960     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28341     Document Type: Article

References (53)

1. Friedman, J.M. 1999. Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89:1-6.
2. Ozonoff, S. 1999. Cognitive impairment in neurofibromatosis type 1. Am. J. Med. Genet. 89:45-52.
3. North, K. 2000. Neurofibromatosis type 1. Am. J. Med. Genet. 97:119-127.
4. Korf, B.R. 2002. Clinical features and pathobiology of neurofibromatosis 1. J. Child Neurol. 17:573-577; discussion 602-604, 646-651.
5. Fossali, E., et al. 2000. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr. Nephrol. 14:806-810.
6. Lin, A.E., et al. 2000. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am. J. Med. Genet. 95:108-117.
7. Riccardi, V.M. 1989. Neurofibromatosis update. Neurofibromatosis. 2:284-291.
8. Gutmann, D.H., et al. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 278:51-57.
9. North, K.N. 1998. Clinical aspects of neurofibromatosis 1. Eur. J. Paediatr. Neurol. 2:223-231.
10. Birnbaum, R.A., et al. 2000. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol. Cell. 5:189-195.
11. Side, L., et al. 1997. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med. 336:1713-1720.
12. Cichowski, K., and Jacks, T. 2001. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 104:593-604.
13. DeClue, J.E., et al. 1992. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 69:265-273.
14. Garicochea, B., Giorgi, R., Odone, V.F., Dorlhiac-Llacer, P.E., and Bendit, I. 1998. Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia. Leuk. Res. 22:1003-1007.
15. Klose, A., et al. 1998. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum. Mol. Genet. 7:1261-1268.
16. Upadhyaya, M., et al. 1997. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum. Genet. 99:88-92.
17. Hiatt, K.K., Ingram, D.A., Zhang, Y., Bollag, G., and Clapp, D.W. 2001. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J. Biol. Chem. 276:7240-7245.
18. Dasgupta, B., and Gutmann, D.H. 2005. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J. Neurosci. 25:5584-5594.
19. The, I., et al. 1997. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science. 276:791-794.
20. Guo, H.F., The, I., Hannan, F., Bernards, A., and Zhong, Y. 1997. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science. 276:795-798.
21. Guo, H.F., Tong, J., Hannan, F., Luo, L., and Zhong, Y. 2000. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Nature. 403:895-898.
22. Corral, T., Jimenez, M., Hernandez-Munoz, I., Perez de Castro, I., and Pellicer, A. 2003. NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity. J. Cell. Physiol. 197:214-224.
23. Abernathy, C.R., et al. 1997. NF1 mutation analysis using a combined heteroduplex/SSCP approach. Hum. Mutat. 9:548-554.
24. Fahsold, R., et al. 2000. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am. J. Hum. Genet. 66:790-818.
25. Xu, H., and Gutmann, D.H. 1997. Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res. 759:149-152.
26. Widemann, B.C., et al. 2006. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J. Clin. Oncol. 24:507-516.
27. Packer, R.J., et al. 2002. Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology. 58:1461-1470.
28. Downward, J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 3:11-22.
29. Efuet, E.T., and Keyomarsi, K. 2006. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res. 66:1040-1051.
30. Pan, J., and Yeung, S.C. 2005. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res. 65:9109-9112.
31. Srinivas, S., et al. 2001. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1:4.
32. Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21:70-71.
33. Su, H., Mills, A.A., Wang, X., and Bradley, A. 2002. A targeted X-linked CMV-Cre line. Genesis. 32:187-188.
34. Brannan, C.I., et al. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 8:1019-1029.
35. Jacks, T., et al. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 7:353-361.
36. Johannessen, C.M., et al. 2005. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. U. S. A. 102:8573-8578.
37. Dasgupta, B., Yi, Y., Chen, D.Y., Weber, J.D., and Gutmann, D.H. 2005. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 65:2755-2760.
38. Gitler, A.D., et al. 2003. Nf1 has an essential role in endothelial cells. Nat. Genet. 33:75-79.
39. Weiss, S.W., Langloss, J.M., and Enzinger, F.M. 1983. Value of S-100 protein in the diagnosis of soft tissue tumors with particular reference to benign and malignant Schwann cell tumors. Lab. Invest. 49:299-308.
40. Frahm, S., et al. 2004. Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol. Dis. 16:85-91.
41. Lakkis, M.M., and Epstein, J.A. 1998. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development. 125:4359-4367.
42. Araki, T., et al. 2004. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 10:849-857.
43. Aoki, Y., et al. 2005. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet. 37:1038-1040.
44. Niihori, T., et al. 2006. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet. 38:294-296.
45. Allanson, J.E., Hall, J.G., and Van Allen, M.I. 1985. Noonan phenotype associated with neurofibromatosis. Am. J. Med. Genet. 21:457-462.
46. Baralle, D., et al. 2003. Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS). Am. J. Med. Genet. A. 119:1-8.
47. Gitler, A.D., et al. 2004. Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia. Pediatr. Res. 55:581-584.
48. Schubbert, S., et al. 2006. Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 38:331-336.
49. Dasgupta, B., Li, W., Perry, A., and Gutmann, D.H. 2005. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 65:236-245.
50. Kisanuki, Y.Y., et al. 2001. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev. Biol. 230:230-242.
51. Zhu, Y., et al. 2001. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15:859-876.
52. Gitler, A.D., Lu, M.M., Jiang, Y.Q., Epstein, J.A., and Gruber, P.J. 2003. Molecular markers of cardiac endocardial cushion development. Dev. Dyn. 228:643-650.
53. Novak, A., Guo, C., Yang, W., Nagy, A., and Lobe, C.G. 2000. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis. 28:147-155.